Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients who meet all of the following criteria are eligible for the study:~* Aged ≥6 years at the time of screening~* VWD type 1 (baseline von Willebrand factor activity \[VWF:Ristocetin Co-factor (RCo)\] \<30 IU/dL, 2A, 2B, 2M, or 3 according to medical history requiring substitution therapy with a VWF-containing product to control bleeding~* Currently receiving on-demand treatment with a VWF-containing product with at least 1, and an average of ≥2, documented spontaneous BEs per month in the last 6 months, with at least 2 of these BEs requiring treatment with a VWF-containing product~* Availability of records to reliably evaluate type, frequency, and treatment of BEs for at least 6 months of on-demand treatment before screening~* Female patients of child-bearing potential must have a negative urine pregnancy test at screening and agree to use adequate birth control measures; in case hormonal contra-ception is used, the medication class should remain unchanged for the duration of the study~* All patients to provide voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted~Exclusion Criteria:~Patients who meet any of the following criteria are not eligible for the study:~* Having received on-demand or prophylactic treatment with a VWF-containing product but having no records available to reliably evaluate the type, frequency, and treatment of BEs over a period of at least 6 months of on-demand treatment~* History, or current suspicion, of VWF or FVIII inhibitors~* Medical history of a thromboembolic event within 1 year before enrolment~* Severe liver or kidney diseases (alanine aminotransferase \[ALAT\] and aspartate trans-aminase \[ASAT\] levels \>5 times of upper limit of normal, creatinine \>120 µmol/L)~* Platelet count \<100,000/µL at screening (except for VWD type 2B)~* Body weight \<20 kg at screening~* Patients receiving, or scheduled to receive, immunosuppressant drugs (other than an-tiretroviral chemotherapy), such as prednisone (equivalent to \>10 mg/day), or similar drugs~* Pregnant or breast-feeding at the time of enrolment~* Cervical or uterine conditions causing abnormal uterine bleeding (including infection, dysplasia)~* Treatment with any IMP in another interventional clinical study currently or within 4 weeks before enrolment~* Other coagulation disorders or bleeding disorders due to anatomical reasons~* Known hypersensitivity to any of the components of the study drug

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): Patients with type 3, type 2 (except 2N), or severe type 1 VWD aged ≥6 years at screening receiving Wilate for prophylactic treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete